Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.65 |
| ▸ | CDC25B | P30305 | 1/20 | 0.65 |
| ▸ | CDC25C | P30307 | 1/20 | 0.65 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | S100A4 | P26447 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 2/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401595 | 0.83 | CDC25A (0.82) | CDC25ACDC25BCDC25CSLC9A1S100A4 | |
| SCHEMBL2398970 | 0.80 | CDC25A (0.68) | CDC25ACDC25BCDC25CSLC9A1JAK2 | |
| SCHEMBL1917955 | 0.79 | CDC25A (1.00) | CDC25ACDC25BCDC25CSLC9A1S100A4 | |
| SCHEMBL2404338 | 0.75 | CDC25A (0.68) | CDC25ACDC25BCDC25CSLC9A1S100A4 | |
| SCHEMBL2399299 | 0.75 | CDC25A (0.67) | CDC25ACDC25BCDC25CSLC9A1S100A4 | |
| SCHEMBL2399058 | 0.73 | CDC25A (0.62) | CDC25ACDC25BCDC25CSLC9A1JAK2 | |
| SCHEMBL1917951 | 0.73 | CDC25A (0.70) | CDC25ACDC25BCDC25CS100A4PTPN1 | |
| SCHEMBL1916506 | 0.72 | CDC25A (0.85) | CDC25ACDC25BCDC25CSLC9A1KMT2A | |
| SCHEMBL1918438 | 0.72 | CDC25A (0.85) | CDC25ACDC25BCDC25CS100A4KMT2A | |
| SCHEMBL1917277 | 0.71 | CDC25A (0.64) | CDC25ACDC25BCDC25CS100A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-11-05 | — | — | US | claimed |
| EP-1831209-B1 | CDC25 PHOSPHATASE INHIBITORS | IPSEN PHARMA (FR) | 2009-08-12 | — | — | EP | claimed |
| US-8017637-B2 | Inhibitors of cdc phosphatases | IPSEN PHARMA S.A.S. (FR) | 2011-09-13 | — | — | US | disclosed |
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-11-05 | — | — | US | disclosed |
| EP-1831209-B1 | CDC25 PHOSPHATASE INHIBITORS | IPSEN PHARMA (FR) | 2009-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275624-A1 | INHIBITORS OF CDC PHOSPHATASES | CDC25C, CDC25A, CDC25B | CDC25A 2/4885CDC25B 3/4885CDC25C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.